In the wake of the AHA presentation many folks were scratching their heads as to why the overwhelming efficay of RVX 208 within the below median LDL-C cohort...you included.  But, you began thinking about why, and hypothesized an explanation (or two)?

Does this June issue of the Diabetes Journal confirm, or change your thinking.  I think this article is bullish for the future of our drug - and advances how science will look at T2D.

...or maybe a nothingburger

https://diabetes.diabetesjournals.org/content/early/2020/06/01/db19-1134